Loading...
•
Jan 29, 2021
Medtronic Q3 2021 Earnings Report
Medtronic's Q3 2021 financial results reflected a slight increase in revenue and a decrease in earnings per share.
Key Takeaways
Medtronic reported a Q3 revenue of $7.775 billion, a 0.8% increase as reported, but a 1.0% decrease organically. The GAAP diluted EPS was $0.94, while the non-GAAP diluted EPS was $1.29, both decreasing by 10%. The company's performance was impacted by the resurgence of COVID-19, which affected procedure volumes.
Q3 revenue increased 0.8% as reported, but decreased 1.0% organically.
GAAP diluted EPS was $0.94, while non-GAAP diluted EPS was $1.29, both decreasing by 10%.
U.S. revenue decreased 2%, representing 51% of the total revenue.
The company experienced growth in specific areas such as Leadless Pacemakers and Respiratory Interventions, while others like Coronary & Structural Heart faced declines.
Medtronic
Medtronic
Medtronic Revenue by Segment
Medtronic Revenue by Geographic Location
Revenue by Segment
Cardiac Rhythm & HF Revenue
CapyFin.comStructural Heart & Aortic Revenue
CapyFin.comCoronary & Peripheral Vascular Revenue
CapyFin.comCranial & Spinal Technologies Revenue
CapyFin.comSpecialty Therapies Revenue
CapyFin.comNeuromodulation Revenue
CapyFin.comSurgical & Endoscopy Revenue
CapyFin.comAcute Care & Monitoring Revenue
CapyFin.comDiabetes Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Medtronic is not providing formal annual or quarterly financial guidance at this time due to the uncertainty caused by the COVID-19 pandemic.
Revenue & Expenses
Visualization of income flow from segment revenue to net income